



01-30-01

GAV 1623

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicants: J. P. Patel *et al.*

Attorney Docket No.: AB1130P0910US

Serial No.: 09/524,113

6475 JS.02

Filed: 03/13/00

Group Art Unit: 1623

For: Novel Formulations Comprising)
Lipid-Regulating Agents)

Examiner: Not Yet Assigned)

RECEIVED
JAN 29 2001
FBI CENTER 1600/2900#9
AW
2-9-01SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTCommissioner for Patents
Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37.C.F.R. Sec. 1.56, it is respectfully requested that this Second Supplemental Information Disclosure Statement be entered and the references listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed references are enclosed for the convenience of the Examiner.

Respectfully submitted,

By Martin L. Katz
Martin L. Katz, Reg. No. 25,011ROCKEY, MILNAMOW & KATZ, LTD.
180 North Stetson Avenue, Suite 4700
Chicago, Illinois 60601
(312) 616-5400CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage at Express Mail Label No. EL733165372US in an envelope addressed to:

Commissioner for Patents, Washington, D.C. 20231 on January 29, 2001.

Carla Phillips